Dr Reddys re-launches OTC drug Famotidine in US
Hyderabad and Princeton: Drugmaker, Dr. Reddy's Laboratories Ltd., has recently announced the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).
Dr. Reddy's OTC Famotidine Tablets USP, 10 mg and 20 mg, are acid reducers that prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages.
"We are pleased to continue to expand our OTC Antacid portfolio for our customers and consumers," says Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories. "This launch will help us fulfil an important therapy gap created in Antacids market due to Ranitidine withdrawal."
The Pepcid AC brand and generic had U.S. sales of approximately $211 million for the most recent twelve months ending in August 2020 according to IRi*.
Dr. Reddy's OTC Famotidine Tablets USP, 10 mg and 20 mg, are available in multiple pack sizes to allow consumers a variety of purchasing options.
Pepcid AC is a registered trademark of Johnson & Johnson.
Read also: Dr Reddys, RDIF get DCGI nod for Russian Covid vaccine trial
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
